Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study | Zendy

Helen R. Stagg | Zendy; James Brown | Zendy; Elmira Ibraim | Zendy; Vija Riekstiņa | Zendy; Piret Viiklepp | Zendy; Andra Cīrule | Zendy; Horia Cocei | Zendy; Manfred Danilovitš | Zendy; Gunta Dravniece | Zendy; Charlotte Jackson | Zendy; Peter J White | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Author(s) -

Helen R. Stagg,

James Brown,

Elmira Ibraim,

Vija Riekstiņa,

Piret Viiklepp,

Andra Cīrule,

Horia Cocei,

Manfred Danilovitš,

Gunta Dravniece,

Charlotte Jackson,

Peter J White

Publication year - 2015

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0142425

Subject(s) - tuberculosis , regimen , medicine , drug resistance , multiple drug resistance , extensively drug resistant tuberculosis , drug , drug resistant tuberculosis , cross sectional study , mycobacterium tuberculosis , pharmacology , biology , pathology , microbiology and biotechnology

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004–13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate drug susceptibility testing and drug susceptibility testing data are vital to inform the development of comprehensive, flexible, multidrug resistant tuberculosis guidance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research